All In Biotech

Drug Trial Radar · NCT01703702

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline

Last checked: Nov 19, 2026Latest source record: Aug 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 641 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

641

Actual

Start

Oct 2012

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Avid RadiopharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Oct 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

Conditions

  • Alzheimer's Disease

Interventions

  • florbetapir (18F)Drug

    Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical and Diagnostic Change in Patient ManagementTime frame: Baseline and 3 months
  2. Change in ADAS-Cog 11 Total ScoreTime frame: Baseline and 12 months

Locations

57 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Sun City, Arizona

  • Research Site

    Clearwater, Florida

  • Research Site

    Miami Beach, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Chestnut Hill, Massachusetts

  • Research Site

    Quincy, Massachusetts

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Patchogue, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Providence, Rhode Island

  • Research Site

    Providence, Rhode Island

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Bennington, Vermont

  • Research Site

    Amiens, France

  • Research Site

    Bordeaux, France

  • Research Site

    Bron, France

  • Research Site

    Dijon, France

  • Research Site

    Lille, France

  • Research Site

    Marseille, France

  • Research Site

    Montpellier, France

  • Research Site

    Nancy, France

  • Research Site

    Nantes, France

  • Research Site

    Nice, France

  • Research Site

    Paris, France

  • Research Site

    Pessac, France

  • Research Site

    Reims, France

  • Research Site

    Rouen, France

  • Research Site

    Strasbourg, France

  • Research Site

    Toulouse, France

  • Research Site

    Tours, France

  • Research Site

    Villeurbanne, France

  • Research Site

    Bergamo, Italy

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.